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Aim. To synthesize a series of novel 3H-thiazolo[4,5-b]pyridine-2-ones by structural modification of the core he-
terocycle in its N3- and N6-positions and to evaluate their anticancer activity in vitro on several tumor cell lines.
Methods. Organic synthesis,
1
H-NMR spectroscopy, trypan blue cell viability assay. Results. A new convenient
synthetic approach was developed and optimized conditions were studied for the reaction of preparation of 3H-
thiazolo[4,5-b]pyridin-2-one derivatives. 5,7-Dimethyl-3H-thiazolo[4,5-b]pyridin-2-one and 6-phenylazo-5,7-
dimethyl-3H-thiazolo[4,5-b]pyridin-2-one were obtained by [3 + 3]cyclocondensation of 4-iminothiazolidone-
2 with acetylacetone and -phenylazoacetylacetone in methanol medium in the presence of sodium methylate.
They were used as starting compounds for further structural modification of the core thiazolo[4,5-b]pyridine he-
terocycle in its 3- and 6-positions. On the basis of in vitro cytotoxicity studies of synthesized compounds several
structure-functional relationships underlying anticancer potential of 5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-
2-one derivatives were identified. Conclusions. 3H-thiazolo[4,5-b]pyridin-2-one can be considered as a promi-
sing molecular scaffold for rational design of potential anticancer drug candidates. Introduction of phenylazo
substitute at C6-position of 3H-thiazolo[4,5-b]pyridin-2-one proved to be the most efficient, as it led to 3-fold in-
crease of its anticancer potential.
Keywords: thiazolo[4,5-b]pyridines, [3+ 3]cyclocondensation, structural modification, antitumor activity.
Introduction. The development of diverse strategies
for the directed synthesis of potential drug candidates
consists of several steps, starting from scaffold hop-
ping towards the hit compounds identification and their
further in silico rational design. Molecular scaffold-ba-
sed design of 4-thiazolidine analogs is inspired by both
the variety of their pharmacological actions and accessi-
bility of chemical modification of their structure. A se-
ries of 4-thiazolidines are at different stages of clinical
trials as anti-inflammatory, antitumor, antimicrobial,
antiviral, cardiovascular and thrombolytic drug candi-
dates [1].
The thiazolidine based heterocycles and their ana-
logs fused w³th the pyridine ring serve as attractive tar-
gets for developing efficient protocols to prepare thia-
zolo[4,5-b]pyridine scaffolds the biological activity of
which still remains poorly studied.
There is little information available about the biolo-
gical activity of thiazolo[4,5-b] pyridines. For examp-
le, some of their derivatives were described as useful
antimicrobial agents effective against a variety of human
and veterinary pathogens including Gram-positive and
Gram-negative aerobic and anaerobic bacteria, as well
asmycobacteria [2]. Thiazolo[4,5-b]pyridines also show
potent inhibitory activities for A42 fibrillization at a
micromolar level for Alzheimer’s disease treatment [3],
some of them are H3 receptor antagonists [4], others
were revealed to activate the GK enzyme in vitro and
significantly reduce glucose levels [5]. Some thiazolo
[4,5-b]pyridine analogues are potent antistaphylococ-
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cal compounds with suboptimal drug-like properties
[6]. They act as inhibitors of the bacterial cell-division
protein, FtsZ. Several compounds among these substan-
ces were found to possess fungicidal action [7] or act as
antagonists of metabotropic glutamate receptors 5
(mGluR5) [8], as well as epidermal growth factor re-
ceptors [9] and a number of other enzymes [10, 11].
However, the information on antitumor activity of
the mentioned bicycle derivatives of 4-thiazolidones is
still missing. Up to now just a few compounds of such
chemical structure have been tested against some hu-
man tumor cell lines in vitro [1, 12]. Several studies
point out that 4-thiazolidone based bicyclic analogues,
in particular pyrazole and isoxazole derivatives, can act
as inhibitors of HSP90, an ATP-dependent molecular
chaperon [12].
In normal cells HSP90 is involved in protein folding,
but in cancer cells it can stabilize oncoproteins v-Src,
Bcr/Abl and mutant products of p53 gene, thus pos-
sessing strong anti-apoptotic activity [13]. Several
HSP90 inhibitors, such as geldanamycin, have already
shown some promising effects in clinical trials [14], but
search for other small molecule inhibitors of HSP90
still remains an active area of cancer research.
Tyrosine Kinases (TK) are other possible antican-
cer targets for 4-thiazolidone derivatives. TK play a cru-
cial role in the action of epidermal growth factor re-
ceptor (EGFR), and mutation of the ATP-binding site
of EGFR is closely associated with TK activity, being
one of the main reasons of cell malignization by dis-
rupting the formation of tumorigenic signals. That’s
why the development of TK inhibitors is suggested as
one of the most perspective strategies for cancer treat-
ment, and some of them, such as trastuzumab (Hercep-
tin®), gefitinib, imatinib have been already widely used
in cancer treatment. Several five-membered hetero-
cycle derivatives and fused heterocycle analogs were
also found to possess the TK enzymes inhibitory activi-
ty and now are at different phases of clinical trials [15].
Based on these data, the main aim of current work
was the development of novel innovative approaches
for organic synthesis of thiazolo[4,5-b]pyridine deriva-
tives with an eye towards the discovery of isosteric
fused ring compounds with the nitrogen heteroatom as
a potential atom interacting with the anticancer targets
mentioned above.
Materials and methods. Synthetic routine for the
novel compounds preparation was carried out accor-
ding to common approaches used for the potential drug
candidates rational design with proper «Merck» (Ger-
many) chemicals implementation.
The structures of all synthesized compounds were
established on the basis of quantitative elemental analy-
sis and spectral 1H-NMR data («Varian Mercury VX-
400», DMSO-d6 was used as a solvent, tetramethylsi-
lane as a standard).
Murine leukemia cells of L1210 line were obtained
from the cell culture collection of R. E. Kavetsky Institu-
te of Experimental Pathology, Oncology and Radiobio-
logy, NAS of Ukraine, human breast adenocarcinoma
cells of MDA-MD-231 lines were obtained from the
cell culture collection of Ludwig Institute for Cancer Re-
search (Sweden), and human melanoma cells of SK-
MEL-28 line were obtained from the cell culture collec-
tion of Nencki Institute of Experimental Biology PAN
(Poland). Cells were cultured in DMEM medium sup-
plemented with 10 % fetal calf serum («Sigma Chemi-
cal Co.», USA), 50 µg/ml streptomycin («Sigma Che-
mi cal Co.»), 50 units/ml penicillin («Sigma Chemical
Co.») in 5 % CO2-containing humidified atmosphere at
37 oC.
For experiments, cells were seeded into 24-well tis-
sue culture plates («Greiner Bio-one», Germany). A cyto-
toxic effect of antitumor drugswas studied under the Evo-
lution 300 Trino microscope («Delta Optical», Poland)
after cell staining with trypan blue dye (0.1 %) [16].
Experiments were performed in triplicate and repea-
ted 3 times. Significance of the difference in a typical
experiment was assessed by Student’s t-test. The level
of significance was set at 0.05.
Results and discussion. In our previous report we
have proposed a convenient method of 5,7-dimethyl-
3H-thiazolo[4,5-b]pyridin-2-one preparation. The me-
thod of thiazolo[4,5-b]pyridine scaffold construction is
based on [3 + 3] cyclocondensation of 4-iminothiazoli-
done-2 on account of its N,C-binucleophilic properties
with dielectrophilic reagents like acetylacetone for-
ming 5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-2-one (1)
[17]. We discovered that a high yield of the product in
the developed protocol can be achieved by keeping the
reagents mixture in methanol in the presence of sodium
methylate over 5 days.
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Further structural modification of thiazolo[4,5-b]py-
ridine scaffold in its N3 and C6 positions was investiga-
ted resulting in the preparation of its novel derivatives.
The optimized conditions were used to obtain 6-
phenylazo-5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-2-
one (2) by involving -phenylazoacetylacetone into
the reaction.
Taking advantage of a good hydrogen atommobili-
ty in NH group of the compound 1N3-position allowed
us to carry out its cyanoethylation which led us to de-
signing 3-(5,7-dimethyl-2-oxo-thiazolo[4,5-b]pyridi-
ne-3-yl)-propionitrile (3) further utilized by hydroly-
sis for [the] 3-(5,7-dimethyl-2-oxo-thiazolo[4,5-b] pyri-
dine-3-yl)-propionic acid (4) preparation.
3-(5,7-dimethyl-6-phenylazo-2-oxo-thiazolo[4,5-b]
pyridine-3-yl)-propionitrile (5) was similarly obtained
in a good yield by involving the compound 2 into cya-
noethylation reaction under the same conditions as out-
lined in the Fig. 1.
The acidic character of the proton in the core hete-
rocycle N3-position of compounds 1 and 2 promotes
tendency of these compounds to transform into corres-
ponding potassium salts under their treatment with po-
tassium hydroxide. The obtained salts possess nucleo-
philic properties and can be involved into reactions with
electrophilic reagents in mild conditions. Thus the po-
tassium salt of 5,7-dimethyl-3H-thiazolo[4,5-b]pyri-
din-2-one and the same salt of 6-phenylazo-5,7-dime-
thyl-3H-thiazolo[4,5-b]pyridin-2-one (6) were alkyla-
ted with monochloracetic acid ethyl ester.
The next step of our strategy was the utilization of
the products in the hydrazinolysis reaction with the res-
pective hydrazides preparation like 5,7-dimethyl-3H-
thiazolo[4,5-b]pyridin-2-one hydrazide (7). In the sa-
me way the compound 2 hydrazide is easily available
while its further utilization in condensation with hetero-
cyclic aldehyde reaction led us to the compound 8 for-
mation. Using 3-bromopropene-1 as an alkylation agent
for the compound 7 treatment allows us to get com-
pound 9 (Fig. 2).
The reduction decoupling reaction of 5,7-dime-
thyl-6-phenylazo-3H-thiazolo[4,5-b]pyridine-2-one (2)
was studied in order to obtain 6-amine-5,7-dimethyl-
3H-thiazolo[4,5-b]pyridine-2-one as a reagent for thia-
zolo[4,5-b] pyridines C6-position transformations. A
high yield of the targeted compound 10was found to oc-
cur in acetic acid-pyridine medium, zinc powder being
used as a reduction agent. The amine group presence in
its C6-position allows transforming it into appropriate
6-acetylaminoderivative (11). Dioxane was found to be
the most suitable medium for the reaction of compound
10 with acetic acids chloroanhydride. The product of
the compound 10 acylation with chloroacetylchloride
made it possible to design 6-sulfanylacetamidederiva-
tive of the core bicycle (12) by treatment it with the ap-
propriate thiol (Fig. 3).
We studied a cytotoxic effect of 12 synthesized com-
pounds in vitro onmurine leukemia cells of L1210 line,
human breast adenocarcinoma cells of MDA-MD-231
line and human melanoma cells of SK-MEL-28 line
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Fig. 1. Synthesis of 5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-2-one (1), 6-phenylazo-5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-2-one (2), the pro-
ducts of their cyanoethylation (3, 5) and hydrolysis (4) reactions
(Fig. 4, a–c). For convenience these compounds were
numerated as T-1–T-12.
The core compound T-1 (5,7-dimethyl-3H-thiazo-
lo[4,5-b]pyridin-2-one) demonstrated the weakest cyto-
toxic effect on all three cell lines (growth inhibition of
L1210 cells only by 25 % compared to control, MDA-
MD-231 cells by 29 % and SK-MEL-28 cells only by
13 % at highest concentration 100 µM). However, the
addition of phenylazo fragment to C6-position of 5,7-
dimethyl-3H-thiazolo[4,5-b]pyridin-2-one molecule
significantly (2–4 times) enhanced the anticancer poten-
tial of core scaffold. It was revealed that resulting T-2
inhibited the growth of L1210 cell by 65 %, MDA-
MD-231 cells by 82 % and SK-MEL-28 cells by 72 %
at 100 µM concentration. The conjugation of beta-cya-
noethyl group at N3-position of core scaffold also boos-
ted its anticancer activity, but to much lower extent
when compared to C6-subsituted compound T-2 (37 %
growth inhibition of L1210 cells, 64 % inhibition of
MDA-MD-231 and 66 % inhibition of SK-MEL-28
cells).
However, the hydrolysis of compound T-3 side
chain weakened its anticancer potential – we observed
18 % inhibition of L1210 cells, while for carcinoma
cells no statistically significant differences between
T-3 and T-4 were found – 60 % inhibition of MDA-
MD-231 cells (compared to 64 % in case of T-3) and
56 % inhibition of SK-MEL-28 cells (compared to
66 % in case of T-3). Thus, the terminal cyano group at
N3-position of 5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-
2-one derivatives seems to play some role in their anti-
leukemic activities.
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Fig. 2. Synthesis of 5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-2-one and 6-phenylazo-5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-2-one potassium
salts and their structural modifications in 3-position
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Fig. 3. Structural modification products of 6-phenylazo-5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-2-one in its 6-position
The conjugation of both phenylazo fragment to C6-
position and beta-cyanoethyl group to N3-position of
core compoundT-1 did not give any cumulative effect –
cytotoxic activity of T-5 on L1210 leukemia cells was
practically the same as of T-3 and weaker than that of
T-2 (39 % of growth inhibition at 100 µM concen-
tration of T-5 compared to 37 % by T-3 and 65 % by
T-2). T-5 demonstrated a bit stronger effect on carci-
noma cells of MDA-MD-231 line, than on leukemia
cells (66 % of growth inhibition compared to 64 % by
T-3), and the same was true for SK-MEL-28 cells (70 %
of growth inhibition compared to 66 % by T-3). Thus,
one can see that beta-cyanoethyl group inhibits the ac-
tivity of phenylazo fragment in «hybrid»moleculeT-5,
which suggests usage of other substitution groups at N3-
position of T-1 for enhancement of its activity.
Taking into consideration that T-2 possesses rela-
tively high anticancer activity, but is insoluble in water,
we synthesized its potassium salt. However, such pro-
cedure led to almost complete loss of anticancer acti-
vity of water-solubleT-6 compound (growth inhibition
of L1210 cells by only 19 % at 100 µM concentration
compared to 65 % inhibition by T-2, 12 % of MDA-
MD-231 cells compared to 82 % by T-2). Only mela-
noma cells of SK-MEL-28 line remained sensitive to
T-6 (64 % growth inhibition compared to 72 % in case
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Fig. 4. Comparison of cytotoxic activity of 5,7-dimethyl-3H-thiazolo [4,5-b]pyridin-2-one derivatives in murine L1210 leukemia cells (a), in
human breast adenocarcinoma cells of MDA-MD-231 line (b) and human melanoma cells of SK- MEL-28 line (c)
of T-2). This suggests specificity of the action of potas-
sium salt of 5,7-dimethyl-6-[phenylazo]-3H-thiazolo
[4,5-b]pyridin-2-one (T-6) towards melanoma cells,
which can be of high importance when moving to in vi-
vo studies on experimental animals.
The next step of our study was further optimization
of the core T-1 scaffold by obtaining hydrazide of this
compound, named T-7 (2-(5,7-dimethyl-2-oxo-3a,4-
dihydrothiazolo[4,5-b]pyridin-3-yl) acetohydrazide).
Interestingly, T-7 demonstrated a weaker cytotoxic ef-
fect towards leukemia and carcinoma cells compared to
the parental compound T-1 (8 % inhibition of L1210
cells compared to 25 % by T-1 and 14 % of growth
inhibition ofMDA-MD-231 cells compared to 29% by
T-1). However, SK-MEL-28 cells were more sensitive
to T-7 action compared to T-1 (47 % of growth inhi-
bition compared to 13 % by T-1). Thus, the hydrazide
group in N3-position of 5,7-dimethyl-3H-thiazolo [4,
5-b]pyridin-2-one is responsible for higher affinity of
the T-7 compound to melanoma cells.
For further evaluation of influence of other N3-po-
sition substitutes in the T-2 molecule (5,7-dimethyl-6-
[phenylazo]-3H-thiazolo[4,5-b]pyridin-2-one) aldehyde
was conjugated to hydrazide of T-2 involving four-
steps synthetic strategy. In contrast to the T-6 and T-7
compounds, which demonstrated higher affinity to me-
lanoma cells,T-8was more specific to leukemia cells –
its cytotoxic effect was the same as of T-2 (61 % of
growth inhibition compared to 65% byT-2), while car-
cinoma and melanoma cells were significantly more
resistant to the T-8 action compared to T-2 (47 % of
MDA-MD-231 cells compared to 82 % in case of T-2
and 48 % on SK-MEL-28 cells compared to 72 % in
case of T-2). In conclusion, conjugation with aldehyde
has not given any significant anticancer effect to T-2,
which suggests that for preservation of the highest an-
ticancer activity of T-2 scaffold (5,7-dimethyl-6-[phe-
nylazo]-3H-thiazolo[4,5-b]pyridin-2-one) no substitu-
tes should be placed at N3-position.
Almost identical results were observed when a pro-
pionic group was conjugated to N3-position of T-2 (5,
7-dimethyl-6-[phenylazo]-3H-thiazolo[4,5-b]pyridin-
2-one). The resulting compound T-9was weaker than
T-2 in all three tested cell lines (35 % growth inhibi-
tion of L1210 cells compared to 65 % by T-2, 47 % of
MDA-MD-231 cells compared to 82 % by T-2 and
43 % of SK-MEL-28 cells compared to 72 % by T-2).
These results give an additional proof that no substitu-
tes should be placed at N3-position for preservation of
the highest anticancer activity of T-2 scaffold .
The next part of the work was dedicated to study-
ing the influence of different substitutes in C6-position
of T-1 core scaffold. At the first step phenylazo frag-
ment was reduced to amino group, and the resulting T-
10 compound completely preserved its anti-melanoma
cytotoxic effect (72,5 % growth inhibition of SK-
MEL-28 cells compared to 72% byT-2), while its anti-
carcinoma effect (52 % of growth inhibition of MDA-
MD-231 cells compared to 82 % by T-2) and anti-
leukemia activity (29 % of growth inhibition compared
to 65 % by T-2) were significantly weaker than those
of parental compound. Thus, the exchange of phenyl-
azo group at C6-position for amino group somehow de-
creases the affinity of 5,7-dimethyl-3H-thiazolo [4,5-b]
pyridin-2-one scaffold to leukemia cells. A similar phe-
nomenon was observed when cyano terminal motif in
T-3was hydrolyzed to acid inT-4, asmentioned before.
The acylation of amino group at C6-position of T-
10 scaffold led to further decrease in its cytotoxic acti-
vity – the resulting compound T-11 was weaker than
its predecessor in carcinoma and melanoma cells (14 %
growth inhibition of MDA-MD-231 cells compared to
52 % by T-10 and only 37 % inhibition of SK-MEL-28
melanoma cells compared to 72.5 % by T-10), while
sensitivity of L1210 leukemia cells remained the same
(30 % growth inhibition of L1210 leukemia cells com-
pared to 29 % in case of T-10).
Under the interaction of a product of acylation of
aminogroup of T-10 by chloroacetylchloride with one
of thiols, the T-12 compound was prepared. Interes-
tingly, we observed a slight increase in anti-carcinoma
effect of T-12 on MDA-MD-231 cells (66 % growth
inhibition compared to 52 % effect of T-10), while its
anti-leukemia action remained the same as of the paren-
tal compound (34 % growth inhibition of L1210 cells
compared to 29 % effect of T-10). In contrast to these
data, SK-MEL-28 melanoma cells demonstrated decre-
ased sensitivity to T-12 (34 % growth inhibition compa-
red to 72.5 % by T-10). Thus, further steric modifica-
tions decrease the anticancer potential of the amino-
group at C6-position of the core scaffold and thus are
not effective.
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According to these results, several principal sugges-
tions could be derived. Despite the introduction of va-
rious substitutes into the 5,7-dimethyl-3H-thiazolo[4,
5-b]pyridin-2-one core molecule, we did not succeed
in significant enhancement of their anticancer activity.
The average cytotoxic activity of the most potent com-
pound with anticancer activity T-2 (6-phenylazo-5,7-
dimethyl-3H-thiazolo[4,5-b]pyridin-2-one) towards
three cell lines was only 50 µM, which is still 10 times
more than that of some clinically used anticancer drugs.
Thus, further modifications in the structure of 6N-de-
rivatives of 5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-2-
one should be done in order to enhance its anticancer
potential, as well as to perform in-depth studies of its
potential targets in tumour cells. Previously we repor-
ted that conjugation of various side groups to 4-thiazo-
lidone core could lead to the induction of different cell
death pathways by such compounds [18]. However, in
that case the chemical structure of substitutes had a lit-
tle effect on the selectivity of action of these 4-thiazo-
lidones toward leukemia and carcinoma cells. Here,
one can see completely different situation, when ex-
change of a single atom can lead to complete loss of the
compound activity towards specific cell line (e. g., leu-
kemia, carcinoma, melanoma). Such data indicate a dis-
tinctive mechanism of action of thiazolo[4,5-b]pyridi-
ne derivatives compared to the previously studied 4-
thiazolidones.
Conclusions. A few structure-functional relation-
ships determining the anticancer potential of the 5,7-di-
methyl-3H-thiazolo[4,5-b]pyridin-2-one derivatives
could be drawn on a basis of the data obtained. The
amino group at C6-position of core scaffold seems to be
important for anti-melanoma activity of the resulting
compound, while the phenylazo group at the same po-
sition is responsible for a wider spectrum of cytotoxic
activities. The biggest anticancer effect was observed
under conjugation of the phenylazo group to C6-posi-
tion of 5,7-dimethyl-3H-thiazolo[4,5-b]pyridin-2-one.
None of used substitutes at N3-position alone had any
significant effect which could be compared to that of
the phenylazo group at C6-position. Thus, for further
enhancement of the cytotoxic activity ofT-2 , the addi-
tional arylazo substitutes should be introduced into C6-
position of this lead compound. Such experiments are
in progress.
Ò. ². ×àáàí, Ð. Ð. Ïàí÷óê, Î. Â. Êëåí³íà, Í. Ð. Ñêîðîõ³ä,
Â. Â. Îãóðöîâ, ². Ã. ×àáàí
Ñèíòåç òà âèâ÷åííÿ ïðîòèïóõëèííî¿ àêòèâíîñò³ äåÿêèõ
ò³àçîëî[4,5-b] ï³ðèäèí³â
Ðåçþìå
Ìåòà. Ñèíòåçóâàòè ñåð³þ íîâèõ ïîõ³äíèõ 3H-ò³àçîëî[4,5-b]ï³ðè-
äèí-2-îíó, ìîäèô³êóþ÷è ñòðóêòóðó áàçîâîãî ãåòåðîöèêëó çà 3-ì ³
6-ì ïîëîæåííÿìè. Äîñë³äèòè ïðîòèïóõëèííó àêòèâí³ñòü îäåð-
æàíèõ ñïîëóê in vitro íà äåÿêèõ ë³í³ÿõ çëîÿê³ñíèõ êë³òèí ññàâö³â.
Ìåòîäè. Îðãàí³÷íèé ñèíòåç, ÏÌÐ-ñïåêòðîñêîï³ÿ, âèçíà÷åííÿ
æèòòºçäàòíîñò³ êë³òèí çà ¿õí³ì çàáàðâëåííÿì òðèïàíîâèì ñè-
í³ì. Ðåçóëüòàòè. Çàïðîïîíîâàíî çðó÷íèé ñèíòåòè÷íèé ï³äõ³ä ³
çíàéäåíî îïòèìàëüí³ óìîâè äëÿ ïðîâåäåííÿ ðåàêö³é îòðèìàííÿ
3H-ò³àçîëî[4,5-b]ï³ðèäèí-2-îí³â. Ðåàêö³ºþ [3 + 3] öèêëîêîíäåíñà-
ö³¿ 4-³ì³íî-2-ò³àçîë³äîíó ç àöåòèëàöåòîíîì ³-ôåí³ëàçîàöåòèëà-
öåòîíîì ó ñåðåäîâèù³ ìåòàíîëó çà ïðèñóòíîñò³ ìåòèëàòó íàò-
ð³þ îäåðæàíî 5,7-äèìåòèë-3H-ò³àçîëî[4,5-b]ï³ðèäèí-2-îí ³ 6-ôå-
í³ëàçî-5,7-äèìåòèë-3H-ò³àçîëî[4,5-b]ï³ðèäèí-2-îí, ÿê³ âèêîðè-
ñòàíî ÿê âèõ³äí³ ðå÷îâèíè äëÿ ìàéáóòíüî¿ ñòðóêòóðíî¿ ìîäèô³-
êàö³¿ áàçîâîãî ò³àçîëî[4,5-b]ï³ðèäèíîâîãî ãåòåðîöèêëó çà 3-ì ³
6-ì ïîëîæåííÿìè. Ââåäåííÿì âèõ³äíèõ ñïîëóê ó ðåàêö³¿ ö³àíîåòè-
ëþâàííÿ ç ïîäàëüøèì ã³äðîë³çîì îòðèìàíîãî ïðîäóêòó àëê³ëóâàí-
íÿ, ÿêå â³äáóâàºòüñÿ ÷åðåç ñòàä³þ îäåðæàííÿ â³äïîâ³äíèõ êàë³é-
íèõ ñîëåé, ç íàñòóïíèì ã³äðàçèíîë³çîì ïðîäóêò³â, à òàêîæ ó ðåàê-
ö³þ â³äíîâëþâàëüíîãî ðîçùåïëåííÿ ç äàëüøèì àöèëþâàííÿì ïðî-
äóêò³â îäåðæàíî ñåð³þ íîâèõ ïîõ³äíèõ 3H-ò³àçîëî[4,5-b]ï³ðèäèí-
2-îíó. Âèñíîâêè. Ò³àçîëî[4,5-b]ï³ðèäèí-2-îí ìîæíà ââàæàòè
ïåðñïåêòèâíèì ìîëåêóëÿðíèì êàðêàñîì, ùî äîçâîëÿº çàñòîñîâó-
âàòè çàçíà÷åíó êîíäåíñîâàíó ñèñòåìó äëÿ ðàö³îíàëüíîãî äèçàéíó
ïîòåíö³éíèõ ë³êàðñüêèõ çàñîá³â ç øèðîêèì ñïåêòðîì ð³çíèõ âèä³â
á³îëîã³÷íî¿ àêòèâíîñò³. Íàéåôåêòèâí³øèì âèÿâèëîñÿ ââåäåííÿ â
6-òå ïîëîæåííÿ ò³àçîëî[4,5-b]ï³ðèäèí-2-îíó ôåí³ëàçî çàì³ñíè-
êà, ùî äàëî ìîæëèâ³ñòü óòðè÷³ ï³äâèùèòè éîãî ïðîòèïóõëèííèé
ïîòåíö³àë.
Êëþ÷îâ³ ñëîâà: ò³àçîëî[4,5-b]ï³ðèäèíè, [3+3] öèêëîêîíäåí-
ñàö³ÿ, ñòðóêòóðíà ìîäèô³êàö³ÿ, ïðîòèïóõëèííà àêòèâí³ñòü.
Ò. È. ×àáàí, Ð. Ð. Ïàí÷óê, Å .Â. Êëåíèíà, Í. Ð. Ñêîðîõèä,
Â. Â. Îãóðöîâ, È. Ã. ×àáàí
Ñèíòåç è èçó÷åíèå ïðîòèâîîïóõîëåâîé àêòèâíîñòè
íåêîòîðûõ òèàçîëî[4,5-b]ïèðèäèíîâ
Ðåçþìå
Öåëü. Ñèíòåçèðîâàòü ñåðèþ íîâûõ ïðîèçâîäíûõ 3H-òèàçîëî[4,5-
b]ïèðèäèí-2-îíà, ìîäèôèöèðóÿ ñòðóêòóðó áàçîâîãî ãåòåðîöèêëà
â 3-ì è 6-ì ïîëîæåíèÿõ. Èññëåäîâàòü ïðîòèâîîïóõîëåâóþ àêòèâ-
íîñòü ïîëó÷åííûõ ñîåäèíåíèé in vitro íà íåêîòîðûõ ëèíèÿõ çëîêà-
÷åñòåííûõ êëåòîê ìëåêîïèòàþùèõ.Ìåòîäû. Îðãàíè÷åñêèé ñèí-
òåç, ÏÌÐ-ñïåêòðîñêîïèÿ, îïðåäåëåíèå æèçíåñïîñîáíîñòè êëå-
òîê îêðàøèâàíèåì òðèïàíîâûì ñèíèì. Ðåçóëüòàòû. Ïðåäëîæåí
óäîáíûé ñèíòåòè÷åñêèé ïîäõîä è óñòàíîâëåíû îïòèìàëüíûå
óñëîâèÿ äëÿ ïðîâåäåíèÿ ðåàêöèé ïîëó÷åíèÿ 3H-òèàçîëî[4,5-b]ïè-
ðèäèí-2-îíîâ. Ðåàêöèåé [3+3] öèêëîêîíäåíñàöèè 4-èìèíî-2-òèà-
çîëèäîíà ñ àöåòèëàöåòîíîì è -ôåíèëàçîàöåòèëàöåòîíîì â ñðå-
äå ìåòàíîëà â ïðèñóòñòâèè ìåòèëàòà íàòðèÿ ïîëó÷åíû 5,7-äè-
ìåòèë-3H-òèàçîëî[4,5-b]ïèðèäèí-2-îí è 6-ôåíèëàçî-5,7-äèìåòèë-
3H-òèàçîëî[4,5-b] ïèðèäèí-2-îí, êîòîðûå èñïîëüçîâàíû êàê èñ-
õîäíûå âåùåñòâà äëÿ áóäóùåé ñòðóêòóðíîé ìîäèôèêàöèè áàçîâî-
ãî òèàçîëî[4,5-b]ïèðèäèíîâîãî ãåòåðîöèêëà â 3-ì è 6-ì ïîëîæå-
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íèÿõ. Ââåäåíèåì èñõîäíûõ ñîåäèíåíèé â ðåàêöèè öèàíîýòèëèðîâà-
íèÿ ñ ïîñëåäóþùèì ãèäðîëèçîì ïîëó÷åííîãî ïðîäóêòà àëêèëèðî-
âàíèÿ, ïðîõîäÿùåãî ÷åðåç ñòàäèþ âûäåëåíèÿ ñîîòâåòñòâóþùèõ
êàëèéíûõ ñîëåé, ñ äàëüíåéøèì ãèäðàçèíîëèçîì ïðîäóêòîâ, à òàê-
æå â ðåàêöèþ âîññòàíîâèòåëüíîãî ðàñùåïëåíèÿ ñî ñëåäóþùèì
àöèëèðîâàíèåì ïðîäóêòî ïîëó÷åíà ñåðèÿ íîâûõ ïðîèçâîäíûõ 3H-
òèàçîëî[4,5-b]ïèðèäèí-2-îíà. Âûâîäû. Òèàçîëî[4,5-b]ïèðèäèí-
2-îí ìîæíà ñ÷èòàòü ïåðñïåêòèâíûì ìîëåêóëÿðíûì êàðêàñîì,
ïîçâîëÿþùèì èñïîëüçîâàòü óêàçàííóþ êîíäåíñèðîâàííóþ ñèñòå-
ìó äëÿ ðàöèîíàëüíîãî äèçàéíà ïîòåíöèàëüíûõ ëåêàðñòâåííûõ
ñðåäñòâ ñ øèðîêèì ñïåêòðîì ðàçíûõ âèäîâ áèîëîãè÷åñêîé àêòèâ-
íîñòè. Íàèáîëåå ýôôåêòèâíèì îêàçàëîñü ââåäåíèå â 6-å ïîëîæå-
íèå òèàçîëî[4,5-b]ïèðèäèí-2-îíà ôåíèëàçî çàìåñòèòåëÿ, ÷òî
äàëî âîçìîæíîñòü âòðîå ïîâûñèòü åãî ïðîòèâîîïóõîëåâûé ïî-
òåíöèàë.
Êëþ÷åâûå ñëîâà: òèàçîëî[4,5-b]ïèðèäèíû, [3 + 3] öèêëîêîí-
äåíñàöèÿ, ñòðóêòóðíàÿ ìîäèôèêàöèÿ, ïðîòèâîîïóõîëåâàÿ àê-
òèâíîñòü.
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